S-Fas Urinary Excretion Helps to Predict the Immunosuppressive Treatment Outcomes in Patients with Proliferative Primary Glomerulonephritis

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2013 Oct 18

PMID 24133352

Citations 1

Authors

Rafal Zwiech

Affiliations

Soon will be listed here.

Abstract

Deregulation of soluble apoptosis stimulating fragment (sFas) plays an important role in glomerulonephritis (GN). The study assed the influence of immunosuppressive treatment on serum and urine sFas in patients with proliferative (PGN) and non-proliferative (NPGN) GN, and evaluated the potential of sFas measurements in predicting outcomes. Eighty-four patients with GN (45 males and 39 females) were included. Serum concentration (ng/mL) and urinary excretion (ng/mg of urinary creatinine) of sFas were measured before and after the treatment. After 12 months of therapy with steroids and cyclophosphamide, patients were divided into two subgroups according to the treatment results: Responders (R) and Non-Responders (NR). The sFas urinary excretion was reduced after treatment in both PGN and NPGN (from 17.12 ± 15 to 5.3 ± 4.2, P = 0.008 and from 10.11 ± 6.1 to 3.4 ± 3.0, P = 0.039; respectively) whereas the sFas serum concentration remained unchanged. In PGN, pre-treatment urinary sFas concentration was significantly lower in the Responders than in Non-Responders (2.3 ± 3.1 vs 19.4 ± 14.1, P = 0.003), and was lower still than in both R (P = 0.044) and NR (P = 0.042) subgroups with NPGN. The immunosuppressive treatment reduced sFas urinary excretion in proliferative and non-proliferative GN and results suggest that the lower urinary sFas may be linked with favorable therapy outcomes in patients with PGN.

Citing Articles

Macrophage migration inhibitory factor urinary excretion revisited – MIF a potent predictor of the immunosuppressive treatment outcomes in patients with proliferative primary glomerulonephritis.

Zwiech R BMC Immunol. 2015; 16:47.

PMID: 26272322 PMC: 4536780. DOI: 10.1186/s12865-015-0112-1.

References

Fuiano G, Sund S, Mazza G, Rosa M, Caglioti A, Gallo G . Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects. Kidney Int. 2001; 59(3):1052-8. DOI: 10.1046/j.1523-1755.2001.0590031052.x. View

Sumegi V, Haszon I, Bereczki C, Papp F, Turi S . Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and -resistant nephrotic syndrome. Pediatr Nephrol. 2008; 23(7):1085-92. DOI: 10.1007/s00467-008-0771-8. View

DAmico G . Tubulo-interstitial damage in glomerular diseases: its role in the progression of the renal damage. Nephrol Dial Transplant. 1998; 13 Suppl 1:80-5. DOI: 10.1093/ndt/13.suppl_1.80. View

McQuarrie E, Shakerdi L, Jardine A, Fox J, Mackinnon B . Fractional excretions of albumin and IgG are the best predictors of progression in primary glomerulonephritis. Nephrol Dial Transplant. 2010; 26(5):1563-9. DOI: 10.1093/ndt/gfq605. View

Sato M, Konuma T, Yanagisawa N, Haizuka H, Asakura H, Nakashima Y . Fas-Fas ligand system in the peripheral blood of patients with renal diseases. Nephron. 2000; 85(2):107-13. DOI: 10.1159/000045642. View

Menon S, Valentini R . Membranous nephropathy in children: clinical presentation and therapeutic approach. Pediatr Nephrol. 2009; 25(8):1419-28. PMC: 2887508. DOI: 10.1007/s00467-009-1324-5. View

Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009; 32(1):3-107. View

Strutz F, Zeisberg M . Renal fibroblasts and myofibroblasts in chronic kidney disease. J Am Soc Nephrol. 2006; 17(11):2992-8. DOI: 10.1681/ASN.2006050420. View

Sano H, Asano K, Minatoguchi S, Hiraoka J, Fujisawa K, Nishigaki K . Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis. Nephron. 1998; 80(2):153-61. DOI: 10.1159/000045159. View

10.

Kawasaki Y . The pathogenesis and treatment of pediatric Henoch-Schönlein purpura nephritis. Clin Exp Nephrol. 2011; 15(5):648-657. DOI: 10.1007/s10157-011-0478-1. View

11.

Chatziantoniou C, Boffa J, Tharaux P, Flamant M, Ronco P, Dussaule J . Progression and regression in renal vascular and glomerular fibrosis. Int J Exp Pathol. 2004; 85(1):1-11. PMC: 2517455. DOI: 10.1111/j.0959-9673.2004.00376.x. View

12.

Kobayashi Y, TATENO S, HIKI Y, Shigematsu H . IgA nephropathy: prognostic significance of proteinuria and histological alterations. Nephron. 1983; 34(3):146-53. DOI: 10.1159/000183000. View

13.

Glassock R, Cohen A . The primary glomerulopathies. Dis Mon. 1996; 42(6):329-83. DOI: 10.1016/s0011-5029(96)90021-8. View

14.

Lorz C, Ortiz A, Justo P, Duque N, Gomez-Guerrero C, Egido J . Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol. 2000; 11(7):1266-1277. DOI: 10.1681/ASN.V1171266. View

15.

Cheng J, Zhou T, Liu C, Shapiro J, BRAUER M, Kiefer M . Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263(5154):1759-62. DOI: 10.1126/science.7510905. View

16.

Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L . Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011; 22(4):752-61. PMC: 3065230. DOI: 10.1681/ASN.2010040355. View

17.

Oshima S, Kawamura O . Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy. Clin Exp Nephrol. 2008; 12(4):264-269. DOI: 10.1007/s10157-008-0045-6. View

18.

Fujinaka H, Yamamoto T, Feng L, Nameta M, Garcia G, Chen S . Anti-perforin antibody treatment ameliorates experimental crescentic glomerulonephritis in WKY rats. Kidney Int. 2007; 72(7):823-30. DOI: 10.1038/sj.ki.5002424. View

19.

Couser W . Glomerulonephritis. Lancet. 1999; 353(9163):1509-15. DOI: 10.1016/S0140-6736(98)06195-9. View

20.

Halling S, Soderberg M, Berg U . Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience. Pediatr Nephrol. 2008; 24(1):91-7. DOI: 10.1007/s00467-008-0990-z. View